Table of Contents Author Guidelines Submit a Manuscript
Journal of Ophthalmology
Volume 2015, Article ID 102582, 8 pages
http://dx.doi.org/10.1155/2015/102582
Clinical Study

Outcomes and Prognostic Factors of Intravitreal Bevacizumab Monotherapy in Zone I Stage 3+ and Aggressive Posterior Retinopathy of Prematurity

1Department of Ophthalmology, “Iuliu Hațieganu” University of Medicine and Pharmacy, 8 Victor Babeș Street, 400012 Cluj-Napoca, Romania
2“Alfred Rusescu” Institute for Mother and Child Care, 120 Lacul Tei Boulevard, 020395 Bucharest, Romania
3Department of Neuroscience, “Iuliu Hațieganu” University of Medicine and Pharmacy, 8 Victor Babeș Street, 400012 Cluj-Napoca, Romania
4Department of Ophthalmology, Emergency County Hospital, 3-5 Clinicilor Street, 400006 Cluj-Napoca, Romania
5Department of Neonatology, “Iuliu Hațieganu” University of Medicine and Pharmacy, 8 Victor Babeș Street, 400012 Cluj-Napoca, Romania
6Department of Medical Informatics and Biostatistics, “Iuliu Hațieganu” University of Medicine and Pharmacy, 8 Victor Babeș Street, 400012 Cluj-Napoca, Romania

Received 8 December 2014; Revised 7 March 2015; Accepted 23 March 2015

Academic Editor: Juliana L. Dreyfuss

Copyright © 2015 Simona Delia Nicoară et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. A. Micieli, M. Surkont, and A. F. Smith, “A systematic analysis of the off-label use of bevacizumab for severe retinopathy of prematurity,” American Journal of Ophthalmology, vol. 148, no. 4, pp. 536.e2–543.e2, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. C. Lin, S. Chen, C. Tseng, Y. Chang, and J. Hwang, “Effects of ranibizumab on very low birth weight infants with stage 3 retinopathy of prematurity: a preliminary report,” Taiwan Journal of Ophthalmology, vol. 2, no. 4, pp. 136–139, 2012. View at Publisher · View at Google Scholar
  3. A. Travassos, S. Teixeira, P. Ferreira et al., “Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity,” Ophthalmic Surgery Lasers and Imaging, vol. 38, no. 3, pp. 233–237, 2007. View at Google Scholar · View at Scopus
  4. E. J. Chung, J. H. Kim, H. S. Ahn, and H. J. Koh, “Combination of laser photocoagulation and intravitreal bevacizumab (Avastin) for aggressive zone I retinopathy of prematurity,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 245, no. 11, pp. 1727–1730, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. S. Kusaka, C. Shima, K. Wada et al., “Efficacy of intravitreal injection of bevacizumab for severe retinopathy of prematurity: a pilot study,” British Journal of Ophthalmology, vol. 92, no. 11, pp. 1450–1455, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. M. O'Keefe, B. Lanigan, and V. W. Long, “Outcome of zone 1 retinopathy of prematurity,” Acta Ophthalmologica Scandinavica, vol. 81, no. 6, pp. 614–616, 2003. View at Publisher · View at Google Scholar · View at Scopus
  7. Z. Récsán, R. Vámos, and G. Salacz, “Laser treatment of zone I prethreshold and stage 3 threshold retinopathy of prematurity,” Journal of Pediatric Ophthalmology and Strabismus, vol. 40, no. 4, pp. 204–207, 2003. View at Google Scholar · View at Scopus
  8. A. Kychenthal, P. Dorta, and X. Katz, “Zone I retinopathy of prematurity: clinical characteristics and treatment outcomes,” Retina, vol. 26, no. 7, supplement, pp. S11–S15, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. Early Treatment for ROP Cooperative Group, “Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial,” Archives of Ophthalmology, vol. 121, no. 12, pp. 1684–1694, 2003. View at Google Scholar
  10. S.-D. Nicoară, C. Cristian, I. Irimescu, A.-C. Stefanut, and G. Zaharie, “Diode laser photocoagulation for retinopathy of prematurity: outcomes after 7 years of treatment,” Journal of Pediatric Ophthalmology and Strabismus, vol. 51, no. 1, pp. 39–45, 2014. View at Publisher · View at Google Scholar · View at Scopus
  11. H. Quiroz-Mercado, M. A. Martinez-Castellanos, M. L. Hernandez-Rojas, N. Salazar-Teran, and R. V. P. Chan, “Antiangiogenic therapy with intravitreal bevacizumab for retinopathy of prematurity,” Retina, vol. 28, no. 3, pp. S19–S25, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. H. A. Mintz-Hittner, K. A. Kennedy, and A. Z. Chuang, “Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity,” The New England Journal of Medicine, vol. 364, no. 7, pp. 603–615, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. International Committee for the Classification of Retinopathy of Prematurity, “The international classification of retinopathy of prematurity revisited,” Archives of Ophthalmology, vol. 123, no. 7, pp. 991–999, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. A. Garner, I. Ben-Sira, and A. Deutman, “An international classification of retinopathy of prematurity,” British Journal of Ophthalmology, vol. 68, no. 10, pp. 690–697, 1984. View at Publisher · View at Google Scholar · View at Scopus
  15. C.-H. Yang, “Anti-vascular endothelium growth factor therapy for retinopathy of prematurity: a continuing debate,” Taiwan Journal of Ophthalmology, vol. 2, no. 4, pp. 115–116, 2012. View at Publisher · View at Google Scholar
  16. T. Sato, C. Shima, and S. Kusaka, “Vitreous levels of angiopoietin-1 and angiopoietin-2 in eyes with retinopathy of prematurity,” The American Journal of Ophthalmology, vol. 151, no. 2, pp. 353–357, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. H. A. Mintz-Hittner and R. R. Kuffel Jr., “Intravitreal injection of bevacizumab (avastin) for treatment of stage 3 retinopathy of prematurity in zone i or posterior zone II,” Retina, vol. 28, no. 6, pp. 831–838, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. H. A. Mintz-Hittner, “Avastin as monotherapy for retinopathy of prematurity,” Journal of AAPOS, vol. 14, no. 1, pp. 2–3, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. C. Gilbert, A. Fielder, L. Gordillo et al., “Characteristics of infants with severe retinopathy of prematurity in countries with low, moderate, and high levels of development: implications for screening programs,” Pediatrics, vol. 115, supplement 2, pp. e518–e525, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. L. J. Faia and M. T. Trese, “Retinopathy of prematurity,” S. Ryan, A. Schachat, C. Wilkinson, D. Hinton, and P. Wiedemann, Eds., vol. 2, pp. 1920–1932, Elsevier, New York, NY, USA, 5th edition, 2013. View at Google Scholar
  21. A. Mataftsi, S. A. Dimitrakos, and G. G. W. Adams, “Mediators involved in retinopathy of prematurity and emerging therapeutic targets,” Early Human Development, vol. 87, no. 10, pp. 683–690, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. L. Kong, H. A. Mintz-Hittner, R. L. Penland, F. L. Kretzer, and P. Chévez-Barrios, “Intravitreous bevacizumab as anti–vascular endothelial growth factor therapy for retinopathy of prematurity: a morphologic study,” Archives of Ophthalmology, vol. 126, no. 8, pp. 1161–1163, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. R. Axer-Siegel, Z. Herscovici, M. Hasanreisoglu, I. Kremer, Y. Benjamini, and M. Snir, “Effect of intravitreal bevacizumab (Avastin) on the growing rabbit eye,” Current Eye Research, vol. 34, no. 8, pp. 660–665, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. S. J. Bakri, M. R. Snyder, J. M. Reid, J. S. Pulido, and R. J. Singh, “Pharmacokinetics of intravitreal bevacizumab (Avastin),” Ophthalmology, vol. 114, no. 5, pp. 855–859, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. R. L. Avery, “Bevacizumab (Avastin) for retinopathy of prematurity: wrong dose, wrong drug, or both?” Journal of AAPOS, vol. 16, no. 1, pp. 2–4, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. S. Y. Jang, K. S. Choi, and S. J. Lee, “Delayed-onset retinal detachment after an intravitreal injection of ranibizumab for zone 1 plus retinopathy of prematurity,” Journal of AAPOS, vol. 14, no. 5, pp. 457–459, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. D. Lepore, G. E. Quinn, F. Molle et al., “Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity,” Ophthalmology, vol. 121, no. 11, pp. 2212–2219, 2014. View at Publisher · View at Google Scholar